Brief: CytoDyn Files Protocol With U.S. FDA For Phase 2 Clinical Trial For Covid-19 Patients With Long-Hauler Symptoms
17/11/2020 14:06
Nov 17 (Reuters) - Cytodyn Inc CYDY.PK :
* CYTODYN FILES PROTOCOL WITH U.S. FDA FOR PHASE 2 CLINICAL
TRIAL
FOR COVID-19 PATIENTS WITH LONG-HAULER SYMPTOMS
Source text for Eikon: ID:nGNX6dWRxT
Further company coverage: CYDY.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cytodyn
See all newsBrief: Cytodyn Appoints Robert E. Hoffman As Chief Executive Officer
Brief: Cytodyn Closes $17.5 Million Financing To Fund Continued Development Of Leronlimab
Brief: CytoDyn Inc Files For Offering Of Up To 120 Million Shares Of Common Stock By Selling Stockholder - SEC Filing
Brief: Cytodyn Files For Mixed Shelf Of Up To $100 Million - SEC Filing
Brief: CytoDyn Announces First Patient Dosed in Phase II Oncology Trial in Colorectal Cancer